Survival outcomes of squamous cell carcinoma arising from sinonasal inverted papilloma: report of 6 cases with systematic review and pooled analysis

• Published in: American journal of otolaryngology Vol. 30; no. 1; pp. 38 - 43
• Main Authors: Tanvetyanon, Tawee, Qin, Dahui, Padhya, Tapan, Kapoor, Rachna, McCaffrey, Judith, Trotti, Andy
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 2009; Elsevier; Elsevier Limited
• Subjects: Adult; Aged; Biological and medical sciences; Biopsy, Needle; Carcinoma, Squamous Cell - mortality; Carcinoma, Squamous Cell - pathology; Carcinoma, Squamous Cell - therapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Dermatology; Female; Follow-Up Studies; Humans; Immunohistochemistry; Male; Medical sciences; Middle Aged; Neoplasm Staging; Otolaryngology; Otorhinolaryngologic Surgical Procedures - methods; Otorhinolaryngology. Stomatology; Papilloma, Inverted - mortality; Papilloma, Inverted - pathology; Papilloma, Inverted - therapy; Paranasal Sinus Neoplasms - mortality; Paranasal Sinus Neoplasms - pathology; Paranasal Sinus Neoplasms - therapy; Radiotherapy, Adjuvant; Sampling Studies; Surgery; Survival Analysis; Treatment Outcome; Tumors of the skin and soft tissue. Premalignant lesions; Inverted papilloma; Skin disease; Squamous cell carcinoma; Basal cell carcinoma; Prognosis; ENT; Malignant tumor; Review; Paranasal sinus; Survival; Nose; Benign neoplasm; Bibliographic review; Cancer
• ISSN: 0196-0709; 1532-818X; 1532-818X
• DOI: 10.1016/j.amjoto.2008.02.005

Inverted papilloma (IP) is an uncommon sinonasal tumor. Squamous cell carcinoma (SCC) is associated with IP in about 7% of cases. To date, there has been no pooled analysis to formulate a survival outcome associated with this rare condition. We retrospectively reviewed the medical records of patients with IP and SCC treated at our institution during 1999–2007. Including our series, a systematic review of literature on Medline database and pooled analysis were performed to establish a survival estimate. Six patients were identified. Squamous cell carcinoma was metachronous to the initial diagnosis of IP in 1 case and synchronous in 5 cases. Of 5 patients who had completed therapy at the time of this report, only 1 remained disease-free at 74 months. The median overall survival in our series was 33 months. Three patients developed distant metastases in brain, lung, bone, and liver. Literature review and pooled survival analysis consisting of 76 cases indicated a median overall survival of 126 months with 3- and 5-year survival rates of 63% and 61%, respectively. Although the survival outcome of SCC arising from IP seems comparable with sinonasal SCCs, some patients with this disease do have a highly aggressive disease, including hematogenous distant metastasis. Overall, about 40% of patients will die of the disease within the first 3 years.